Austedo and new approvals accelerate Teva's growth turnaround
- Austedo reached its $2.5 billion sales target a year ahead of schedule in Q3 2026.
- The FDA approved Weltruza, adding a major long-acting injectable to Teva's schizophrenia franchise.
- Biosimilar revenue exceeded its $800 million goal a year early, turning a former drag into a growth asset.
- Austedo, Ajovy, and Uzedy are the main growth engines offsetting a $1.1 billion generic Revlimid decline.
- Teva reached a U.S. tariff agreement to protect select innovative drugs, though generic tariff risks remain.
The turnaround gains external validation
Teva is transitioning from a slow-growth generic drug company to a mix of generics, biosimilars, and higher-margin branded medicines. Q3 2026 results accelerated this narrative. Austedo hit its $2.5 billion sales target a year ahead of schedule, and the FDA approved Weltruza. Strong growth across the branded portfolio prompted management to raise full-year guidance for its key assets.
This growth matters because Teva is losing a massive stream of revenue from generic Revlimid, with management expecting about $1.1 billion of pressure in 2026. The bull case is that Teva can use its newer branded drugs, growing biosimilars, and cost savings to keep growing while margins improve, fully covering the Revlimid gap. The biosimilar segment achieved its $800 million goal a year early.
The pipeline also took steps forward. Teva acquired BXCL501 from BioXcel for acute agitation, strengthening its psychiatric portfolio. It also discontinued the emrusolmin Phase II study after an interim futility analysis, focusing resources on higher-probability assets like ecopipam and duvakitug.
The bear case notes that the core generics business remains somewhat soft without Revlimid. If Austedo slows down due to channel inventory changes or IRA pricing impacts in 2027, the growth engine could stall. An October 2026 U.S. tariff agreement protects some innovative drugs, but generic products still face tariff uncertainty. The FTC review of inhaler patents and a restarted TAPI sale also add risk.
Generics scale meets branded drugs
Teva makes money by selling prescription medicines. A large part of the company is generic drugs, which are lower-cost versions of branded drugs after exclusivity ends. This business benefits from global distribution and a massive product catalog, but it faces constant pricing pressure.
The newer growth side is branded medicine. Austedo, Ajovy, Uzedy, and the newly approved Weltruza have patent protection and stronger pricing power. That product mix shift is the core of Teva's growth plan.
Teva also sells biosimilars, which are close copies of complex biologic drugs. The company now has 15 products on the market, turning the category into a major growth pillar. The pipeline includes duvakitug, DARI, and ecopipam. These represent options on future growth.
The balance sheet is recovering, though financial health remains a vulnerability. Selling TAPI, its active pharmaceutical ingredient business, would help reduce debt further. The first exclusive talks ended in 2025, and a renewed sale process is currently under way.
The drugs that matter most
Austedo
Austedo is Teva's most important growth drug, hitting its $2.5 billion target a year early in Q3 2026.
Ajovy
Ajovy treats migraine prevention. It continues to grow and outperform internal expectations.
Uzedy and Weltruza
Uzedy and Weltruza are long-acting injectable schizophrenia medicines that give Teva a highly competitive psychiatric franchise.
Global generics
Generics remain Teva's broad base business. The segment is stable when excluding the steep Revlimid decline.
Biosimilars
Biosimilars bridge generics and branded drugs. Teva now has 15 products in the market and hit its $800 million goal a year early.
Ecopipam
Teva submitted the ecopipam application in June 2026 for pediatric Tourette syndrome, with FDA action expected in early 2027.
Duvakitug
Duvakitug is an anti-TL1A asset in Phase 3 trials, recently expanded into hidradenitis suppurativa and Crohn's disease.
U.S. growth carries the mix
The segment mix uses full-year 2025 revenue from Teva's 2025 Form 10-K. The United States is the clear growth center.
What could break the setup
Revlimid cliff overwhelms growth
High impact · Medium oddsTeva faces about $1.1 billion of 2026 revenue pressure from lower generic Revlimid sales. Management expects newer medicines to cover this gap. If they fall short, overall revenue growth targets are at risk.
Austedo slows
High impact · Medium oddsAustedo is the largest growth engine. Elevated channel inventory could disrupt near-term revenue, and the IRA implementation in 2027 could pressure pricing. Any sharp slowdown would weaken the peak sales case.
Tariff uncertainty on generics
Medium impact · Medium oddsWhile Teva reached a U.S. agreement in late 2026 to protect specific innovative products from tariffs, the broader generic and non-patented portfolio remains exposed to policy changes. Broad tariffs could squeeze generic margins.
TAPI sale slips again
Medium impact · Medium oddsTeva wants to sell TAPI, its active pharmaceutical ingredient business, to help reduce debt. Exclusive talks ended in 2025, and a renewed sale process began. A weak price or no deal would slow balance sheet repair.
FTC inhaler patent action
Medium impact · Medium oddsThe FTC is investigating Teva's Orange Book patent listings for certain inhaler products. An adverse result could mean legal costs, penalties, or faster generic competition.
In one breath
What does Teva Pharmaceutical do?
Teva sells prescription drugs around the world. It is best known for generic drugs, but its growth now depends more on branded medicines like Austedo, Ajovy, and Uzedy.
Why is Revlimid important for Teva?
Teva sells a generic version of Revlimid, called lenalidomide capsules. That revenue is falling in 2026, and management has pointed to about $1.1 billion of pressure from the decline.
What is the main bull case for TEVA stock?
The bull case is that Teva's newer branded medicines keep growing fast enough to cover the Revlimid decline. If that happens while debt falls and margins rise, the turnaround gets more credible.
What is the biggest risk for Teva?
The biggest near-term risk is that growth drugs do not fully cover the 2026 Revlimid headwind. The TAPI sale and the FTC inhaler patent probe are also important risks to watch.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - Specialty & Generic companies
Companies near Teva Pharmaceutical Industries Limited in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

